-transparent.png){kind=logo}
A patient with ovarian cancer under long-term hemodialysis was treated with carboplatin at 240 mg/m2 via intravenous drip infusion for 30 min. Hemodialysis was performed 1 or 2 hrs after the administration of carboplatin. The pharmacokinetics of carboplatin were determined, plasma total and free carboplatin-derived platinum (total Pt and free Pt) levels declined rapidly in the former. The AUC, T1/2 and Cmax of total and free Pt were estimated to be 7.14 and 3.14 mg/ml x min, 35.1 and 18.2 h, and 15.1 and 10.0 micrograms/ml, respectively. Plasma total and free Pt levels showed the same as normal control in the latter. The AUC, T1/2 and Cmax of total and free Pt were estimated to be 8.70 and 5.09 mg/ml x min, 27.6 and 21.9 h, and 13.2 and 13.2 micrograms/ml, respectively. No severe side effect was observed after administration of carboplatin. In conclusion, carboplatin may be given to the patient 2 hrs before hemodialysis in view of the pharmacokinetics.
H Kurata, and
N Yoshiya, and
H Ikarashi, and
T Kaneko, and
S Kodama, and
K Tanaka, and
K Suzuki, and
H Yoshizawa, and
T Cho, and
E Suzuki
February 2014,
Pharmacotherapy,
H Kurata, and
N Yoshiya, and
H Ikarashi, and
T Kaneko, and
S Kodama, and
K Tanaka, and
K Suzuki, and
H Yoshizawa, and
T Cho, and
E Suzuki
March 2012,
Cancer chemotherapy and pharmacology,
H Kurata, and
N Yoshiya, and
H Ikarashi, and
T Kaneko, and
S Kodama, and
K Tanaka, and
K Suzuki, and
H Yoshizawa, and
T Cho, and
E Suzuki
January 2009,
European journal of gynaecological oncology,
H Kurata, and
N Yoshiya, and
H Ikarashi, and
T Kaneko, and
S Kodama, and
K Tanaka, and
K Suzuki, and
H Yoshizawa, and
T Cho, and
E Suzuki
February 1994,
International journal of oncology,
H Kurata, and
N Yoshiya, and
H Ikarashi, and
T Kaneko, and
S Kodama, and
K Tanaka, and
K Suzuki, and
H Yoshizawa, and
T Cho, and
E Suzuki
July 2003,
Gan to kagaku ryoho. Cancer & chemotherapy,
H Kurata, and
N Yoshiya, and
H Ikarashi, and
T Kaneko, and
S Kodama, and
K Tanaka, and
K Suzuki, and
H Yoshizawa, and
T Cho, and
E Suzuki
January 1994,
Nephron,
H Kurata, and
N Yoshiya, and
H Ikarashi, and
T Kaneko, and
S Kodama, and
K Tanaka, and
K Suzuki, and
H Yoshizawa, and
T Cho, and
E Suzuki
October 1995,
Journal of clinical pharmacology,
H Kurata, and
N Yoshiya, and
H Ikarashi, and
T Kaneko, and
S Kodama, and
K Tanaka, and
K Suzuki, and
H Yoshizawa, and
T Cho, and
E Suzuki
June 2003,
Ryumachi. [Rheumatism],
H Kurata, and
N Yoshiya, and
H Ikarashi, and
T Kaneko, and
S Kodama, and
K Tanaka, and
K Suzuki, and
H Yoshizawa, and
T Cho, and
E Suzuki
January 2002,
Nephron,
H Kurata, and
N Yoshiya, and
H Ikarashi, and
T Kaneko, and
S Kodama, and
K Tanaka, and
K Suzuki, and
H Yoshizawa, and
T Cho, and
E Suzuki
May 2010,
Oncology letters,
